Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, molecular diagnostics company Exact Sciences (EXAS 1.80%) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Exact Sciences and see what CAPS investors are saying about the stock right now.
Exact Sciences facts
|
|
|
|
Headquarters (founded) |
Madison, Wis. (1995) |
|
Market Cap |
$612.1 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$4.1 million |
|
Management |
CEO Kevin Conroy CFO Maneesh Arora |
|
Return on Equity (average, past 3 years) |
(47.9%) |
|
Cash/Debt |
$108.1 million / $2.0 million |
|
Competitors |
CRH Medical PreMD |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 16% of the All-Star members who have rated Exact Sciences believe the stock will underperform the S&P 500 going forward.
Earlier this week, one of those Fools, zzlangerhans, touched on the stock's seemingly unsustainable valuation:
A [$600M] market cap is way too much for unconvincing sensitivity and specificity data that don't provide a convincing basis for widespread adoption of the Cologuard test. Exact is once again a trader's football and I expect the stock to move with the winds until a concrete catalyst emerges.
